Literature DB >> 14706087

Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole.

M B Kerrn1, N Frimodt-Møller, F Espersen.   

Abstract

Healthy adult volunteers received 1 g of sulphamethizole orally (n = 10) and later 400 mg of pivmecillinam (274 mg of mecillinam) (n = 9). All urine was collected in defined periods over 24 h, and the drug concentrations in urine were determined. For sulphamethizole, the maximum urine concentration for seven subjects was reached in 0-3 h, and for the remaining three in 3-6 h. For mecillinam, eight of the nine subjects attained a maximum urine concentration in 0-3 h, after which the concentration declined rapidly for six subjects in 3-6 h. Strains of Escherichia coli with different MICs for sulphamethizole and mecillinam were exposed to collected urine for 2.5 h and 5 h. The results indicated that a sensitive E. coli population should be suppressed by sulphamethizole in urine for two-thirds of the time (with 1 g twice-daily) and by mecillinam in urine throughout the 24-h period (with 400 mg three times a day). There was a slight but significant correlation between the ex-vivo effect (Delta log10 CFU/mL) and the log10 concentration/MIC ratio after exposure to sulphamethizole for 5 h (r2 = 0.27, p < 0.0001), and a significant correlation between the variables with mecillinam (r2 = 0.66, p < 0.0001).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14706087     DOI: 10.1111/j.1469-0691.2004.00737.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.

Authors:  Elisabeth Thulin; Martin Sundqvist; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

2.  Activity of mecillinam against carbapenem-resistant Enterobacterales.

Authors:  Cécile Emeraud; Alexandre Godmer; Delphine Girlich; Océane Vanparis; Fériel Mahamdi; Elodie Creton; Agnès B Jousset; Thierry Naas; Rémy A Bonnin; Laurent Dortet
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

3.  In vitro activity of mecillinam, temocillin and nitroxoline against MDR Enterobacterales.

Authors:  Lars Plambeck; Frieder Fuchs; Janko Sattler; Axel Hamprecht
Journal:  JAC Antimicrob Resist       Date:  2022-06-16

4.  Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.

Authors:  Lars Bjerrum; Bente Gahrn-Hansen; Per Grinsted
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

5.  High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Silje Bakken Jørgensen; Knut Liestøl; Pål A Jenum
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

6.  Pivmecillinam for Uncomplicated Lower Urinary Tract Infections Caused by Staphylococcus saprophyticus-Cumulative Observational Data from Four Recent Clinical Studies.

Authors:  Filip Jansåker; Marianne Bollestad; Ingvild Vik; Morten Lindbæk; Lars Bjerrum; Niels Frimodt-Møller; Jenny Dahl Knudsen
Journal:  Antibiotics (Basel)       Date:  2019-05-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.